Cognitive effects of Group I metabotropic glutamate receptor ligands in the context of drug addiction - PubMed (original) (raw)
Review
Cognitive effects of Group I metabotropic glutamate receptor ligands in the context of drug addiction
M Foster Olive. Eur J Pharmacol. 2010.
Abstract
Glutamate plays a pivotal role in regulating drug self-administration and drug-seeking behavior, and the past decade has witnessed a substantial surge of interest in the role of Group I metabotropic glutamate receptors (mGlu(1) and mGlu(5) receptors) in mediating these behaviors. As will be reviewed here, Group I mGlu receptors are involved in normal and drug-induced synaptic plasticity, drug reward, reinforcement and relapse-like behaviors, and addiction-related cognitive processes such as maladaptive learning and memory, behavioral inflexibility, and extinction learning. Animal models of addiction have revealed that antagonists of Group I mGlu receptors, particularly the mGlu(5) receptor, reduce self-administration of virtually all drugs of abuse. Since inhibitors of mGlu5 receptor function have now entered clinical trials for other medical conditions and appear to be well-tolerated, a key question that remains unanswered is - what changes in cognition are produced by these compounds that result in reduced drug intake and drug-seeking behavior? Finally, in contrast to mGlu(5) receptor antagonists, recent studies have indicated that positive allosteric modulation of mGlu(5) receptors actually enhances synaptic plasticity and improves various aspects of cognition, including spatial learning, behavioral flexibility, and extinction of drug-seeking behavior. Thus, while inhibition of Group I mGlu receptor function may reduce drug reward, reinforcement, and relapse-related behaviors, positive allosteric modulation of the mGlu5 receptor subtype may actually enhance cognition and potentially reverse some of the cognitive deficits associated with chronic drug use.
Copyright (c) 2010 Elsevier B.V. All rights reserved.
Figures
Fig. 1
Diagram of a dendritic spine and postsynaptic localization of ionotropic and Group I mGlu receptors. Synaptically released glutamate binds to ionotropic glutamate receptors (NMDA, AMPA, and KA receptors), which allows the influx of Na+ and/or Ca2+ ions to depolarize the postsynaptic membrane. Group I mGlu receptors are localized to the perisynaptic annulus of the dendritic spine where they are stimulated by high levels of synaptic glutamate release or glutamate released from glia. Group I mGlu are structurally coupled to NMDA receptor via Homer proteins (as well as other scaffolding proteins not shown), and are biochemically coupled to NMDA receptor function via PKC. Activation of Group I mGlu receptors increases the activity of NMDA receptors (denoted by a +), and NMDA receptor activation can positively influence Group I mGlu receptor function as well.
Fig. 2
The mGlu5 receptor positive allosteric modulator CDPPB reduces extinction responding following intravenous cocaine self-administration. Male Sprague-Dawley rats were trained to self-administer cocaine at a dose of 0.33 mg/kg/infusion under an FR1 schedule of reinforcement in 2 hr daily sessions. Following 12 days of active cocaine self-administration (the average of the last two days is depicted in the graph as SA), animals underwent extinction by eliminating infusions as a consequence of active lever presses, while stimuli that were previously presented during each cocaine infusion (i.e., light/tone stimulus and syringe pump activation) were still presented. Animals were administered vehicle (20% 2-hydroxypropyl-β-cyclodextrin) or CDPPB (30 mg/kg i.p.) 30 min prior to daily 2 hr extinction sessions (E1, E2, or E3). CDPPB significantly (*P<0.05) reduced extinction responding on extinction days E1 and E2, possibly reflecting increased extinction learning, as this dose of CDPPB has no effect on motor activity (Gass and Olive, 2009a).
Similar articles
- Group II metabotropic glutamate receptors (mGlu2/3) in drug addiction.
Moussawi K, Kalivas PW. Moussawi K, et al. Eur J Pharmacol. 2010 Aug 10;639(1-3):115-22. doi: 10.1016/j.ejphar.2010.01.030. Epub 2010 Apr 2. Eur J Pharmacol. 2010. PMID: 20371233 Free PMC article. Review. - The role of metabotropic glutamate receptors in drug reward, motivation and dependence.
Markou A. Markou A. Drug News Perspect. 2007 Mar;20(2):103-8. doi: 10.1358/dnp.2007.20.2.1083435. Drug News Perspect. 2007. PMID: 17440633 Review. - The role of metabotropic glutamate receptors in neurobehavioral effects associated with methamphetamine use.
Hámor PU, Knackstedt LA, Schwendt M. Hámor PU, et al. Int Rev Neurobiol. 2023;168:177-219. doi: 10.1016/bs.irn.2022.10.005. Epub 2022 Nov 28. Int Rev Neurobiol. 2023. PMID: 36868629 Review. - Metabotropic glutamate mGlu1 receptor stimulation and blockade: therapeutic opportunities in psychiatric illness.
Lesage A, Steckler T. Lesage A, et al. Eur J Pharmacol. 2010 Aug 10;639(1-3):2-16. doi: 10.1016/j.ejphar.2009.12.043. Epub 2010 Apr 2. Eur J Pharmacol. 2010. PMID: 20371230 Review. - Metabotropic glutamate receptor ligands as potential therapeutics for addiction.
Olive MF. Olive MF. Curr Drug Abuse Rev. 2009 Jan;2(1):83-98. doi: 10.2174/1874473710902010083. Curr Drug Abuse Rev. 2009. PMID: 19630739 Free PMC article. Review.
Cited by
- Emergence of Endocytosis-Dependent mGlu1 LTD at Nucleus Accumbens Synapses After Withdrawal From Cocaine Self-Administration.
Scheyer AF, Christian DT, Wolf ME, Tseng KY. Scheyer AF, et al. Front Synaptic Neurosci. 2018 Oct 23;10:36. doi: 10.3389/fnsyn.2018.00036. eCollection 2018. Front Synaptic Neurosci. 2018. PMID: 30459590 Free PMC article. - New medications for drug addiction hiding in glutamatergic neuroplasticity.
Kalivas PW, Volkow ND. Kalivas PW, et al. Mol Psychiatry. 2011 Oct;16(10):974-86. doi: 10.1038/mp.2011.46. Epub 2011 Apr 26. Mol Psychiatry. 2011. PMID: 21519339 Free PMC article. Review. - Group III metabotropic glutamate receptors and drug addiction.
Mao L, Guo M, Jin D, Xue B, Wang JQ. Mao L, et al. Front Med. 2013 Dec;7(4):445-51. doi: 10.1007/s11684-013-0291-1. Front Med. 2013. PMID: 24078068 Free PMC article. Review. - Effect of Novel Allosteric Modulators of Metabotropic Glutamate Receptors on Drug Self-administration and Relapse: A Review of Preclinical Studies and Their Clinical Implications.
Caprioli D, Justinova Z, Venniro M, Shaham Y. Caprioli D, et al. Biol Psychiatry. 2018 Aug 1;84(3):180-192. doi: 10.1016/j.biopsych.2017.08.018. Epub 2017 Sep 5. Biol Psychiatry. 2018. PMID: 29102027 Free PMC article. Review. - Deficits in ventromedial prefrontal cortex group 1 metabotropic glutamate receptor function mediate resistance to extinction during protracted withdrawal from an extensive history of cocaine self-administration.
Ben-Shahar O, Sacramento AD, Miller BW, Webb SM, Wroten MG, Silva HE, Caruana AL, Gordon EJ, Ploense KL, Ditzhazy J, Kippin TE, Szumlinski KK. Ben-Shahar O, et al. J Neurosci. 2013 Jan 9;33(2):495-506a. doi: 10.1523/JNEUROSCI.3710-12.2013. J Neurosci. 2013. PMID: 23303930 Free PMC article.
References
- Alagarsamy S, Marino MJ, Rouse ST, Gereau R.W.t., Heinemann SF, Conn PJ. Activation of NMDA receptors reverses desensitization of mGluR5 in native and recombinant systems. Nat. Neurosci. 1999;2:234–240. - PubMed
- Anwyl R. Metabotropic glutamate receptors: electrophysiological properties and role in plasticity. Brain Res. Rev. 1999;29:83–120. - PubMed
- Anwyl R. Metabotropic glutamate receptor-dependent long-term potentiation. Neuropharmacology. 2009;56:735–740. - PubMed
- American Psychiatry Association . Diagnostic and Statistical Manual of Mental Disorders. 4th Edition, Text Revision American Psychiatric Press; Washington DC: 2002.
Publication types
MeSH terms
Substances
Grants and funding
- R01 AA013852/AA/NIAAA NIH HHS/United States
- R01 DA024355-03/DA/NIDA NIH HHS/United States
- DA024355/DA/NIDA NIH HHS/United States
- DA025606/DA/NIDA NIH HHS/United States
- R01 DA025606-01A1/DA/NIDA NIH HHS/United States
- R01 DA024355-05/DA/NIDA NIH HHS/United States
- R01 DA024355/DA/NIDA NIH HHS/United States
- R01 AA013852-09/AA/NIAAA NIH HHS/United States
- R01 AA013852-06A2/AA/NIAAA NIH HHS/United States
- R01 DA025606/DA/NIDA NIH HHS/United States
- R01 DA025606-03/DA/NIDA NIH HHS/United States
- AA013852/AA/NIAAA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous